Protocol MD Launches Nationwide GLP-1 and Peptide Therapy Platform

Physician-supervised GLP-1 prescribing is moving deeper into the direct-to-consumer channel. Protocol MD, the telehealth extension of Scarsdale, New York-based Protocol Health, has launched nationwide services covering GLP-1 weight-loss therapy, peptide protocols, and remote bloodwork — extending the clinic's in-person care model to patients in all 50 states.

The practice was co-founded by Dr. Richard Dentico, a board-certified physiatrist, and his cousin Joe Garvey. The platform is designed to carry patients from initial assessment through ongoing follow-up without interruption, a continuity-of-care model that distinguishes it from prescription-only telehealth services that hand off after the first script.

GLP-1 Meets Peptide Therapy

The service stack positions Protocol MD squarely at the intersection of two of the fastest-moving segments in the weight-management market. GLP-1 receptor agonists — including semaglutide and tirzepatide — have reshaped the obesity-treatment landscape, and their downstream effects on appetite, satiety, and metabolic markers are now driving formulation decisions across the weight management and functional nutrition category. Peptide therapies, while still largely operating under compounding-pharmacy frameworks, are attracting growing consumer interest as adjunct tools for body composition and recovery.

The inclusion of remote bloodwork monitoring is a meaningful clinical differentiator. Tracking biomarkers — including lipid panels, HbA1c, and inflammatory markers — during GLP-1 therapy is standard of care in brick-and-mortar settings but has historically lagged in telehealth-only programs. For operators in the supplement and functional food space, the growing normalization of at-home lab testing opens a parallel opportunity: condition-specific nutritional protocols tied to measurable clinical endpoints rather than structure-function claims alone.

Market Context

The GLP-1 telehealth market has expanded rapidly since 2023, with compounding pharmacies and direct-to-consumer platforms proliferating ahead of anticipated FDA enforcement actions on compounded semaglutide. Protocol MD's physician-led model — anchored by a board-certified specialist rather than a general-practice prescriber — is a positioning bet on clinical credibility as regulatory scrutiny tightens and consumer sophistication around these therapies increases.

For the functional foods and nutraceutical supply chain, the GLP-1 adoption wave carries direct formulation implications. Patients on GLP-1 therapy typically reduce caloric intake significantly, elevating the importance of nutrient-dense, high-protein, and micronutrient-fortified formats that support adequate intake at lower volumes. Ingredient suppliers and finished-product manufacturers developing GLP-1-adjacent protein and satiety-support products are watching platforms like Protocol MD as a signal of where the supervised weight-loss patient is headed next.

Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.